Format
Sort by
Items per page

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 95

1.

DKK1 as a novel target for myeloma immunotherapy.

Qian J, Yi Q.

Oncoimmunology. 2012 Aug 1;1(5):756-758.

2.

Active vaccination with Dickkopf-1 induces protective and therapeutic antitumor immunity in murine multiple myeloma.

Qian J, Zheng Y, Zheng C, Wang L, Qin H, Hong S, Li H, Lu Y, He J, Yang J, Neelapu S, Kwak LW, Hou J, Yi Q.

Blood. 2012 Jan 5;119(1):161-9. doi: 10.1182/blood-2011-07-368472. Epub 2011 Nov 2.

3.

Dickkopf-1 (DKK1) is a widely expressed and potent tumor-associated antigen in multiple myeloma.

Qian J, Xie J, Hong S, Yang J, Zhang L, Han X, Wang M, Zhan F, Shaughnessy JD Jr, Epstein J, Kwak LW, Yi Q.

Blood. 2007 Sep 1;110(5):1587-94. Epub 2007 May 21.

4.
5.

CpG or IFN-α are more potent adjuvants than GM-CSF to promote anti-tumor immunity following idiotype vaccine in multiple myeloma.

Hong S, Qian J, Li H, Yang J, Lu Y, Zheng Y, Yi Q.

Cancer Immunol Immunother. 2012 Apr;61(4):561-71. doi: 10.1007/s00262-011-1123-2. Epub 2011 Oct 15.

6.

Active immunotherapy of multiple myeloma.

Houet L, Veelken H.

Eur J Cancer. 2006 Jul;42(11):1653-60. Epub 2006 Jun 22. Review.

PMID:
16797966
7.

Tumor cells loaded with α-galactosylceramide promote therapeutic NKT-dependent anti-tumor immunity in multiple myeloma.

Hong S, Lee H, Jung K, Lee SM, Lee SJ, Jun HJ, Kim Y, Song H, Bogen B, Choi I.

Immunol Lett. 2013 Nov-Dec;156(1-2):132-9. doi: 10.1016/j.imlet.2013.10.002. Epub 2013 Oct 19.

PMID:
24148970
8.

Myeloma cell line-derived, pooled heat shock proteins as a universal vaccine for immunotherapy of multiple myeloma.

Qian J, Hong S, Wang S, Zhang L, Sun L, Wang M, Yang J, Kwak LW, Hou J, Yi Q.

Blood. 2009 Oct 29;114(18):3880-9. doi: 10.1182/blood-2009-06-227355. Epub 2009 Aug 4.

9.

Inhibiting Dickkopf-1 (Dkk1) removes suppression of bone formation and prevents the development of osteolytic bone disease in multiple myeloma.

Heath DJ, Chantry AD, Buckle CH, Coulton L, Shaughnessy JD Jr, Evans HR, Snowden JA, Stover DR, Vanderkerken K, Croucher PI.

J Bone Miner Res. 2009 Mar;24(3):425-36. doi: 10.1359/jbmr.081104.

10.

In vivo and in vitro effects of a novel anti-Dkk1 neutralizing antibody in multiple myeloma.

Pozzi S, Fulciniti M, Yan H, Vallet S, Eda H, Patel K, Santo L, Cirstea D, Hideshima T, Schirtzinge L, Kuhstoss S, Anderson KC, Munshi N, Scadden D, Kronenberg HM, Raje N.

Bone. 2013 Apr;53(2):487-96. doi: 10.1016/j.bone.2013.01.012. Epub 2013 Jan 17.

11.

Dendritic cell vaccine but not idiotype-KLH protein vaccine primes therapeutic tumor-specific immunity against multiple myeloma.

Wang S, Hong S, Wezeman M, Qian J, Yang J, Yi Q.

Front Biosci. 2007 May 1;12:3566-75.

PMID:
17485322
12.

Dickkopf-1 is a key regulator of myeloma bone disease: opportunities and challenges for therapeutic intervention.

Zhou F, Meng S, Song H, Claret FX.

Blood Rev. 2013 Nov;27(6):261-7. doi: 10.1016/j.blre.2013.08.002. Epub 2013 Sep 2. Review.

13.

Evolution of cellular immunotherapy: from allogeneic transplant to dendritic cell vaccination as treatment for multiple myeloma.

Arnason J, Avigan D.

Immunotherapy. 2012 Oct;4(10):1043-51. doi: 10.2217/imt.12.118. Review.

PMID:
23148756
14.

Immunotherapy using dendritic cells against multiple myeloma: how to improve?

Nguyen-Pham TN, Lee YK, Kim HJ, Lee JJ.

Clin Dev Immunol. 2012;2012:397648. doi: 10.1155/2012/397648. Epub 2012 Mar 15. Review.

15.

Bone marrow stromal cells create a permissive microenvironment for myeloma development: a new stromal role for Wnt inhibitor Dkk1.

Fowler JA, Mundy GR, Lwin ST, Edwards CM.

Cancer Res. 2012 May 1;72(9):2183-9. doi: 10.1158/0008-5472.CAN-11-2067. Epub 2012 Feb 28.

16.

Vaccination with dendritic cell/tumor fusions following autologous stem cell transplant induces immunologic and clinical responses in multiple myeloma patients.

Rosenblatt J, Avivi I, Vasir B, Uhl L, Munshi NC, Katz T, Dey BR, Somaiya P, Mills H, Campigotto F, Weller E, Joyce R, Levine JD, Tzachanis D, Richardson P, Laubach J, Raje N, Boussiotis V, Yuan YE, Bisharat L, Held V, Rowe J, Anderson K, Kufe D, Avigan D.

Clin Cancer Res. 2013 Jul 1;19(13):3640-8. doi: 10.1158/1078-0432.CCR-13-0282. Epub 2013 May 17.

17.

Anti-DKK1 mAb (BHQ880) as a potential therapeutic agent for multiple myeloma.

Fulciniti M, Tassone P, Hideshima T, Vallet S, Nanjappa P, Ettenberg SA, Shen Z, Patel N, Tai YT, Chauhan D, Mitsiades C, Prabhala R, Raje N, Anderson KC, Stover DR, Munshi NC.

Blood. 2009 Jul 9;114(2):371-9. doi: 10.1182/blood-2008-11-191577. Epub 2009 May 5.

18.

Novel immunotherapies.

Yi Q.

Cancer J. 2009 Nov-Dec;15(6):502-10. doi: 10.1097/PPO.0b013e3181c51f0d. Review.

19.

A bioluminescence imaging based in vivo model for preclinical testing of novel cellular immunotherapy strategies to improve the graft-versus-myeloma effect.

Rozemuller H, van der Spek E, Bogers-Boer LH, Zwart MC, Verweij V, Emmelot M, Groen RW, Spaapen R, Bloem AC, Lokhorst HM, Mutis T, Martens AC.

Haematologica. 2008 Jul;93(7):1049-57. doi: 10.3324/haematol.12349. Epub 2008 May 19.

20.

Cellular immunotherapy using dendritic cells against multiple myeloma.

Nguyen-Pham TN, Lee YK, Lee HJ, Kim MH, Yang DH, Kim HJ, Lee JJ.

Korean J Hematol. 2012 Mar;47(1):17-27. doi: 10.5045/kjh.2012.47.1.17. Epub 2012 Mar 28.

Supplemental Content

Support Center